Identification and functional validation of reciprocal microRNA-mRNA pairings in African American prostate cancer disparities

Clinical Cancer Research

Volumn 21, Issue 21, 2015, Pages 4970-4984

  Wang, Bi Dar ^a   Ceniccola, Kristin ^a   Yang, Qi ^a   Andrawis, Ramez ^a   Patel, Vyomesh ^b   Ji, Youngmi ^c   Rhim, Johng ^d   Olender, Jacqueline ^a   Popratiloff, Anastas ^a   Latham, Patricia ^a   Lai, Yinglei ^e   Patierno, Steven R ^f,g   Lee, Norman H ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^d Uniformed Services University of the Health Sciences   (United States)

^e GEORGE WASHINGTON UNIVERSITY   (United States)

^f GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MICRORNA; MICRORNA 133A; MICRORNA 145; MICRORNA 34A; MICRORNA 513C; MICRORNA 96; PROTEIN MCL 1; STAT1 PROTEIN; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; AFRICAN AMERICAN; AGED; APOPTOSIS; ARTICLE; BASE PAIRING; CANCER CELL; CANCER CELL LINE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CARCINOGENESIS; CELL PROLIFERATION; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FOXO3A GENE; GAIN OF FUNCTION MUTATION; GENE EXPRESSION PROFILING; GENE MAPPING; GENE TARGETING; GENETIC ASSOCIATION; GENOMICS; GLEASON SCORE; HEALTH DISPARITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ITPR2 GENE; LOSS OF FUNCTION MUTATION; MALE; MCL1 GENE; POPULATION SPECIFICITY; POPULATION STRUCTURE; PPP2R2A GENE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT1 GENE; TUMOR INVASION; WESTERN BLOTTING; BIOPSY; CANCER GRADING; CANCER STAGING; CLUSTER ANALYSIS; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; REPRODUCIBILITY; RNA INTERFERENCE; TUMOR CELL LINE;

AFRICAN AMERICANS; APOPTOSIS; BIOMARKERS; BIOPSY; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICRORNAS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84947235045     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1566     Document Type: Article

References (50)

1. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61.
2. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
3. Cummins JM, Velculescu VE. Implications of micro-RNA profiling for cancer diagnosis. Oncogene 2006;25:6220-7.
4. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 2004;101:11755-60.
5. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009;4:199-227.
6. Shi XB, Tepper CG, White RW. MicroRNAs and prostate cancer. J Cell Mol Med 2008;12:1456-65.
7. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
8. Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 2007;177:444-9.
9. Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo Y. Investigating Black-White differences in prostate cancer prognosis: a systematic review and meta-analysis. Int J Cancer 2008;123:430-5.
10. Devgan SA, Henderson BE, Yu MC, Shi CY, Pike MC, Ross RK, et al. Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate 1997;33:9-12.
11. Shuch B, Mikhail M, Satagopan J, Lee P, Yee H, Chang C, et al. Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol 2004;22:4725-9.
12. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008;68:927-36.
13. Wang BD, Yang Q, Ceniccola K, Bianco F, Andrawis R, Jarrett T, et al. Androgen receptor-target genes in African American prostate cancer disparities. Prostate Cancer 2013;2013:763569.
14. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008;27:1788-93.
15. Wang L, Tang H, Thayanithy V, Subramanian S, Oberg AL, Cunningham JM, et al. Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 2009;69:9490-7.
16. Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, et al. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res 2009;69:5568-74.
17. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 2004;20:93-9.
18. Tian L, Greenberg SA, Kong SW, Altschuler J, Kohane IS, Park PJ. Discovering statistically significant pathways in expression profiling studies. Proc Natl Acad Sci U S A 2005;102:13544-9.
19. House CD, Vaske CJ, Schwartz AM, Obias V, Frank B, Luu T, et al. Voltage-gated Na+ channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion. Cancer Res 2010;70:6957-67.
20. Wang BD, Kline CL, Pastor DM, Olson TL, Frank B, Luu T, et al. Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network. Mol Cancer 2010;9:98.
21. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008;36:D154-8.
22. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 2010;20:87-90.
23. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:15-31.
24. Zambon AC, Gaj S, Ho I, Hanspers K, Vranizan K, Evelo CT, et al. GO-Elite: a flexible solution for pathway and ontology over-representation. Bioinformatics 2012;28:2209-10.
25. Zhu G, Fan Z, Ding M, Zhang H, Mu L, Ding Y, et al. An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis. Oncogene. 2015 Mar 9. [Epub ahead of print].
26. Han W, Carpenter RL, Cao X, Lo HW. STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation with STAT3. Mol Carcinog 2013;52:959-69.
27. Cronshaw DG, Kouroumalis A, Parry R, Webb A, Brown Z, Ward SG. Evidence that phospholipase-C-dependent, calcium-independent mechanisms are required for directional migration of T-lymphocytes in response to the CCR4 ligands CCL17 and CCL22. J Leukoc Biol 2006;79:1369-80.
28. Krol J, Francis RE, Albergaria A, Sunters A, Polychronis A, Coombes RC, et al. The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther 2007;6:3169-79.
29. Zhang S, Zhau HE, Osunkoya AO, Iqbal S, Yang X, Fan S, et al. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer 2010;9:9.
30. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769-75.
31. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
32. Gade S, Porzelius C, Falth M, Brase JC, Wuttig D, Kuner R, et al. Graph based fusion of miRNA and mRNA expression data improves clinical outcome prediction in prostate cancer. BMC Bioinformatics 2011;12:488.
33. Feng J, Huang C, Diao X, Fan M, Wang P, Xiao Y, et al. Screening biomarkers of prostate cancer by integrating microRNA and mRNA microarrays. Genet Test Mol Biomarkers 2013;17:807-13.
34. Zheng H, Fu R, Wang JT, Liu Q, Chen H, Jiang SW. Advances in the techniques for the prediction of microRNA targets. Int J Mol Sci 2013;14:8179-87.
35. Huang JC, Babak T, Corson TW, Chua G, Khan S, Gallie BL, et al. Using expression profiling data to identify human microRNA targets. Nat Methods 2007;4:1045-9.
36. Mairinger FD, Ting S, Werner R, Walter RF, Hager T, Vollbrecht C, et al. Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study. Mod Pathol 2014;27:1632-40.
37. Patterson SG, Wei S, Chen X, Sallman DA, Gilvary DL, Zhong B, et al. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 2006;25:6113-22.
38. Nohata N, Hanazawa T, Enokida H, Seki N. microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget 2012;3:9-21.
39. Uchida Y, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Kawahara K, et al. MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Urol Oncol 2013;31:115-23.
40. Xu XM, Qian JC, Deng ZL, Cai Z, Tang T, Wang P, et al. Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer. Oncol Lett 2012;4:339-45.
41. Guttilla IK, White BA. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 2009;284:23204-16.
42. Haflidadottir BS, Larne O, Martin M, Persson M, Edsjo A, Bjartell A, et al. Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1. PLoS ONE 2013;8:e72400.
43. Guo H, Li Q, Li W, Zheng T, Zhao S, Liu Z. miR-96 downregulates RECK to promote growth and motility of non-small cell lung cancer cells. Mol Cell Biochem 2014;390:155-60.
44. Zhang J, Kong X, Li J, Luo Q, Li X, Shen L, et al. miR-96 promotes tumor proliferation and invasion by targeting RECK in breast cancer. Oncol Rep 2014;31:1357-63.
45. Lin H, Dai T, Xiong H, Zhao X, Chen X, Yu C, et al. Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLoS ONE 2010;5:e15797.
46. Shukla S, Bhaskaran N, Maclennan GT, Gupta S. Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice. Prostate 2013;73:1507-17.
47. Audenet F, Cancel-Tassin G, Bigot P, Audouin M, Gaffory C, Ondet V, et al. Germline genetic variations at 11q13 and 12p11 locus modulate age at onset for renal cell carcinoma. J Urol 2014;191:487-92.
48. Wu X, Scelo G, Purdue MP, Rothman N, Johansson M, Ye Y, et al. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet 2012;21:456-62.
49. Kojima S, Enokida H, Yoshino H, Itesako T, Chiyomaru T, Kinoshita T, et al. The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J Hum Genet 2014;59:78-87.
50. Melo SA, Kalluri R. Molecular pathways: microRNAs as cancer therapeutics. Clin Cancer Res 2012;18:4234-9.